Abstract
The aim of our studies was to investigate the dissolution characteristics of six extended-release nifedipine tablets with a dosage strength of 20 mg that are marketed in the European Union. All investigated products were homogenous matrix tablets having identical dosing regimens. The products can be substituted for originator products and other ER generic formulations of the same drug load. In the present study, the formulations were tested using USP Apparatus 2 at 50 rpm, which is one of the standard conditions specified by the USP for nifedipine ER tablets. Moreover, investigations under intensified stress conditions were performed with Apparatus 2 at 100 rpm, as well as in a novel biorelevant dissolution stress-test device. A complementary characterization of the integrity of the tablet matrices was performed using a standard disintegration test apparatus. In the applied experimental settings, drug dissolution from all tested formulations proceeded very fast with liberation of at least 15 mg of drug within the first two hours of analysis. The increase in stirring rate from 50 to 100 rpm in Apparatus 2 did not substantially accelerate the dissolution process. Moreover, it was noticed that the tablet matrices had poor mechanical stability and very rapid disintegration behavior under all experimental settings. The disintegration times measured in the standard disintegration test were less than 10 min. The results clearly show that the dissolution characteristics of all tested products are a function of the properties of the drug substance and not the dosage forms. It became obvious that none of the tested formulations fulfilled USP requirements for nifedipine ER tablets specified for Apparatus 2 at 50 rpm. However, the products are marketed in the European Union where the USP quality criteria are not mandatory but only advisable. In our interpretation, such dissolution characteristics bear a potential risk of dosage-form-related interactions in vivo.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
